v3.22.2.2
Revenue Recognition (Tables) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]    
Net revenue $ 1,022.0 $ 1,025.0
Elimination of revenue attributable to multiple locations $ (31.0) (28.0)
Revenue Recognition and Deferred Revenue [Abstract]    
Contractual Liabilities The contract liabilities balances (current and non-current) as of September 30, 2022 and June 30, 2022 are as follows:
(Dollars in millions)
Balance at June 30, 2022$194 
Balance at September 30, 2022$145 
Revenue recognized in the period from amounts included in contracts liability at the beginning of the period:$(91)
  
Geographical [Member]    
Disaggregation of Revenue [Line Items]    
Disaggregation of Revenue
The following table allocates revenue by the location where the goods were made or the service performed:

Three Months Ended  
September 30,
(Dollars in millions)20222021
United States$697 $630 
Europe274351
Other8272
Elimination of revenue attributable to multiple locations(31)(28)
Total$1,022 $1,025 
  
United States    
Disaggregation of Revenue [Line Items]    
Net revenue $ 697.0 630.0
Europe    
Disaggregation of Revenue [Line Items]    
Net revenue 274.0 351.0
International Other    
Disaggregation of Revenue [Line Items]    
Net revenue $ 82.0 $ 72.0
Product and Service[Member]    
Disaggregation of Revenue [Line Items]    
Disaggregation of Revenue
The following tables reflect net revenue for the three months ended September 30, 2022 and 2021, by type of activity and reportable segment (in millions):
Three Months Ended September 30, 2022BiologicsPharma and Consumer HealthTotal
Manufacturing & commercial product supply$94 $292 $386 
Development services & clinical supply429 207 636 
Total$523 $499 $1,022 
Three Months Ended September 30, 2021BiologicsPharma and Consumer HealthTotal
Manufacturing & commercial product supply$134 $276 $410 
Development services & clinical supply414 201 615 
Total$548 $477 $1,025